Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Background: Iron deficiency is common in heart failure and associated with worse outcomes.
We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial …

Objectives: This paper aims to compare the effectiveness of sacubitril-valsartan and
angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in …

One major disorder, heart failure (HF), remains a stubborn problem and is now considered
to be the greatest challenge in cardiovascular medicine and surgery. 5 From a clinical …

Aims The effects of adding a sodium–glucose cotransporter 2 (SGLT2) inhibitor to a
mineralocorticoid receptor antagonist (MRA) or an angiotensin receptor–neprilysin inhibitor …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Despite the advancement in medicine, management of heart failure (HF), which usually
presents as a disease syndrome, has been a challenge to healthcare providers. This is …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Objectives The purpose of this study was to assess the efficacy and safety of dapagliflozin in
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …

Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …